Limitations of the study
somatic hypermutations
This study describes antibodies isolated from a single donor at a single time point. The quality of isolated antibodies is also limited by the source of the study, the VRC 018 clinical trial, which was designed for the primary goal of testing the safety of BG505 DS-SOSIP adjuvanted by alum as a vaccine candidate. As a result, the antibodies isolated have limited somatic hypermutations and low neutralization potency with strain specificity.